DIABETIC DYSLIPIDEMIA - TREATMENT IMPLICATIONS

被引:0
|
作者
BETTERIDGE, DJ
机构
关键词
CARDIOVASCULAR DISEASE; DIABETES; DIABETES TREATMENT; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is associated with increased morbidity and mortality from cardiovascular disease in the absence of the major risk factors-cigarette smoking, hypertension and serum cholesterol concentration. When these risk factors are present, the attributable risk to each factor alone and to the combination of risk factors is higher in diabetic than in nondiabetic subjects. Thus, stringent measures to correct risk factors for cardiovascular disease have been advocated in diabetic patients. In addition to hypercholesterolaemia, other lipid and lipoprotein abnormalities collectively referred to as diabetic dyslipidaemia probably contribute to vascular risk. Hypertriglyceridaemia, often associated with low high-density-lipoprotein cholesterol, is common in NIDDM patients and is associated with insulin resistance. Recent information in diabetic patients, pointing to the association of hypertriglyceridaemia with accumulation of remnant particles and alterations in low-density-lipoprotein subfractions, helps to explain the strong relationship between hypertriglyceridaemia and vascular risk in these individuals. Although there are as yet no intervention trials with lipid-lowering diets or drugs in diabetic patients to judge the impact on vascular disease, national and international bodies have furnished guidelines for the identification and treatment of lipid disorders in diabetes in the hope of reducing the huge toll of vascular disease in these patients.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [1] Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment
    Parhofer, Klaus G.
    CLINICAL LIPIDOLOGY, 2011, 6 (04) : 401 - 411
  • [2] Treatment of diabetic dyslipidemia
    Garg, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (4A): : 47B - 51B
  • [3] TREATMENT OF DIABETIC DYSLIPIDEMIA
    DENKE, MA
    GRUNDY, SM
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1989, 17 (01) : 56 - 58
  • [4] Diabetic dyslipidemia:: assessment and treatment
    Wägner, AM
    Pérez, A
    MEDICINA CLINICA, 2002, 119 (07): : 260 - 264
  • [5] Treatment of dyslipidemia in type II diabetic dyslipidemia patients
    Alemao, EA
    Reckless, J
    Zhang, Q
    Yin, DD
    DIABETOLOGIA, 2002, 45 : A93 - A93
  • [6] A New Treatment Strategy for Diabetic Dyslipidemia?
    Kothari, Vishal
    Bornfeldt, Karin E.
    DIABETES, 2020, 69 (10) : 2061 - 2063
  • [7] Statin therapy for the treatment of diabetic dyslipidemia
    Haffner, SM
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (04) : 280 - 287
  • [8] New strategies for the treatment of diabetic dyslipidemia
    Haffner, SM
    Goldberg, RB
    DIABETES CARE, 2002, 25 (07) : 1237 - 1239
  • [9] Treatment and impact of dyslipidemia in diabetic nephropathy
    Tadashi Toyama
    Miho Shimizu
    Kengo Furuichi
    Shuichi Kaneko
    Takashi Wada
    Clinical and Experimental Nephrology, 2014, 18 : 201 - 205
  • [10] NEW PERSPECTIVES IN THE TREATMENT OF DIABETIC DYSLIPIDEMIA
    Carmena, R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)